Unreleased FDA Compounding Guide Becomes Focus Of House Bill House Energy and Commerce Republicans signaled they may clarify FDA's authority over drug compounding -- particularly the much debated part of the statute that is subject to a circuit court split -- but they held steady on not giving the agency new powers.